Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/ myelodysplastic syndrome: An analysis of the Japan Transplant Outcome Registry

Bone Marrow Transplantation

Volumn 48, Issue 4, 2013, Pages 529-536

  Kurosawa, S ^a   Yakushijin, K ^b   Yamaguchi, T ^c   Atsuta, Y ^d   Nagamura Inoue, T ^e   Akiyama, H ^f   Taniguchi, S ^g   Miyamura, K ^h   Takahashi, S ^e   Eto, T ⁱ   Ogawa, H ^j   Kurokawa, M ^k   Tanaka, J ^l   Kawa, K ^m   Kato, K ^h   Suzuki, R ^d   Morishima, Y ⁿ   Sakamaki, H ^f   Fukuda, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

ⁱ HAMANOMACHI HOSPITAL   (Japan)

^j HYOGO COLLEGE OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^m RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

ⁿ AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

allogeneic hematopoietic cell transplantation; cord blood transplantation; GVHD; leukemia; non relapse mortality

Indexed keywords

BUSULFAN; CYCLOSPORIN A; HLA ANTIGEN; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CAUSE OF DEATH; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CORD BLOOD STEM CELL TRANSPLANTATION; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; JAPAN; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84876409865     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.172     Document Type: Review

References (21)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
2. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 2011; 29: 805-813.
3. Giebel S, Labopin M, Holowiecki J, Labar B, Komarnicki M, Koza V et al. Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Ann Hematol 2009; 88: 1005-1013.
4. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.
5. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269-274.
6. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
7. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
8. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930.
9. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
10. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10: 320-327.
11. Oh H, Loberiza Jr FR, Zhang MJ, Ringden O, Akiyama H, Asai T et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105: 1408-1416.
12. Hahn T, McCarthy Jr PL, Zhang MJ, Wang D, Arora M, Frangoul H et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26: 5728-5734.
13. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
14. Yokoe D, Casper C, Dubberke E, Lee G, Munoz P, Palmore T et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 2009; 44: 495-507.
15. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hemato-poietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
16. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
17. Paulin T, Ringden O, Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987; 1: 317-328.
18. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328-1332.
19. Barrett AJ. Conditioning regimens for allogeneic stem cell transplants. Curr Opin Hematol 2000; 7: 339-342.
20. Feinstein L, Storb R. Reducing transplant toxicity. Curr Opin Hematol 2001; 8: 342-348.
21. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45: 295-302.